SUMMARY HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …

The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to
3 years in phase III studies and a high barrier to resistance in treatment-naive and …

This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along
5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people …

Background The 2-drug regimen dolutegravir plus lamivudine has demonstrated long-term
noninferior efficacy vs 3-/4-drug regimens (3/4DRs) in phase 3 trials. This systematic …

Objectives The aim of the present study was to compare the efficacy and durability of
treatment switch to two‐drug (2DR) vs. three‐drug (3DR) integrase inhibitor (InSTI)‐based …

Background: Results from clinical trials and observational studies suggest that dolutegravir
plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 …

Background Simplified antiretroviral therapy (ART) regimens are desirable for people with
HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir …

Abstract Purpose of Review With the expanded roll-out of antiretrovirals for treatment and
prevention of HIV during the last decade, the emergence of HIV drug resistance (HIVDR) …

Background: The high effectiveness and safety of the two-drug (2DRs) strategy using
dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines …

Introduction: Despite the efficacy and safety of antiretroviral therapy, new treatment options
are needed to address the concerns of patients and physicians regarding long-term …